UK – NICE green light for Cablivi in rare blood-clotting disorder

The UK’s National Institute for Health and Care Excellence (NICE) has given a green light to Sanofi’s Cablivi for acquired thrombotic thrombocytopenic purpura (aTTP) – a rare and potentially life-threatening blood clotting disorder.

The new NICE guidance applies to the treatment of an acute episode of aTTP in adults and in young people aged 12 years and over who weigh at least 40kg.

The decision to recommend Cablivi (caplacizumab) is based on data from the phase III HERCULES study, which compared the efficacy and safety of Cablivi compared to placebo, plus standard of care, in 145 patients with aTTP.

The results from that study showed that Cablivi in addition to standard of care, when compared to placebo, decreased the median time for platelets to recover to normal levels and reduced the risk of death, as well as recurrence of TTP or formation of major clots in blood vessels…